AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04782804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Antibody（Tislelizumab）
Description: PD-1 Antibody（Tislelizumab, 200mg） was given q3w iv.
Study NCT05112848 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Description: Alternating intramuscular (IM) (deltoid) injections of monovalent prototype vaccine premixed with Matrix-M™ adjuvant (0.5 mL) given either as~2 doses (one on Day 0 and one on Day 21 or Day 70) and an injection of placebo (0.5mL) on Day 21 or Day 70, or 3 doses (Day 0, Day 21, and Day 70).
Study NCT05998655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tele nursing
Description: In the research, tele-nursing applications based on technological competence theory will be applied to the experimental group. In the content of the application, training, consultancy and follow-up will be made on breast cancer, the problems experienced in the treatment process of breast cancer, the most frequently experienced chemotherapy symptoms and management strategies. Technology knowledge will be based on the concepts of collaborative design and participant interaction. A five-week group training will be implemented once a week. The training will be applied to all the participants in the experimental group and will be held over Google Meet. Educational program; pre-prepared powerpoint presentations, oral narration, discussion and group training will be made using e-booklets.
Study NCT04826458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TreC-Onco
Description: At the baseline visit, each patient assigned to arm A will be provided with the electronic diary (installed on a smart phone or tablet), the oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the electronic diary, and the user manual will also be given. This app allows patients to record parameters related to their health state (e.g. medications, blood pressure, weight, fever, side effects or other symptoms) and through the alarm function, it reminds the patient to take the tablets, indicating the exact dosage. In addition, the patient can also indicate the dose reduction or the omission.
Study NCT04826458 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Paper diary
Description: Patients assigned to arm B will be provided with a paper diary, oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the paper diary.
Study NCT06364761 — intervention group
Intervention type: PROCEDURE
Intervention: Bag in the lens cataract surgery
Description: Cataract surgery using the Morcher 89A intraocular lens
Study NCT05796882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Food Plant-Based Diet Ad Libitum
Description: Participants will follow a Low Fat Whole Food Plant-Based Diet Ad Libitum for 8 weeks. It consists of increasing the daily consumption of fruits and vegetables, including sources of vegetable protein such as legumes (beans, lentils, chickpeas, peas, etc), soybeans and their derivatives (tofu, textured soybeans, soymilk), and whole grains. (oats, wheat, rice, quinoa, corn), nuts and seeds high in omega-3 fatty acids (chia, flaxseed, hemp), and minimize processed foods, and foods high in saturated fat. Avoiding animal-sourced foods.~There will be no caloric restriction, however, visual support will be provided, in the form of a traffic light, to distinguish the frequency with which each type of food can be consumed
Study NCT05796882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Standard Care
Description: Nutritional Consultation every month for 2 months. Recommendations on healthy eating and lifestyle will be given. Duration 8 weeks
Study NCT06191965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: MitoQ is a synthetic analogue of coenzyme Q10. It is produced by the company Antipodean Pharmaceuticals and is formulated as a stable yellow powder suitable for oral formulation, prepared as capsules of white color. It is a commercial dietary supplement sold over the counter as an antioxidant, to be taken orally once or twice a day. It has subsequently been tested for various clinical conditions in humans.~1. Molecular formula: C38H47O7PS (C37H44O4P.CH3O3S)~2. CAS number: 444890-41-9 (phosphonium cation)~3. Molecular weight: 678.81~4. MitoQ capsules: The standard commercial posology is a 20 mg daily dose. All formulations are produced following Good Manufacturing Practice (GMP) standards (https://www.who.int/medicines/areas/quality_safety/quality_assurance/TRS986annex2.pdf?ua=1).~5. MitoQ will be administered in oral capsules provided by the manufacturer Antipodean Pharma, to be taken once daily, one hour before breakfast. The daily dose will be 2 pills, i.e., 40 mg MitoQ.
Study NCT06191965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills in identical appearance to the MitoQ capsules will be produced and provided by Antipodean Pharma and given to the patients in the control arm two per day to be taken one hour before breakfast. The composition of the placebo is tapioca starch, microcrystalline cellulose, hypromellose, silica-colloidal anhydrous, purified water, carrageenan, and pectin.
Study NCT05028049 — intervention group
Intervention type: OTHER
Intervention: plateau areas
Description: Patients should be long staying residents in plateau areas (altitude level>3000 meters above sea level)
Study NCT05656586 — intervention group
Intervention type: OTHER
Intervention: observational-- no intervention
Description: observational
Study NCT00893854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclophenac
Study NCT06231394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multimodal pelvic floor rehabilitation
Description: A multimodal pelvic floor rehabilitation program will be performed on all children for 10 weeks, two days a week and approximately 45 minutes. A multimodal pelvic floor rehabilitation will include education, bladder and bowel training, manual techniques, exercise training (diaphragmatic breathing exercise, pelvic floor muscle training, trunk stabilization exercises based on developmental kinesiology) and a home program. The home program will be given on other days of the week.
Study NCT05149443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: theory-based mHealth-intervention (app)
Description: Measuring the effect of the buddy and gamification components separately. During the A1 phase (baseline) and the A2 phase (reversal), participants will be asked not to use the 'Move it, Move ID' intervention: the app will be blocked. After an A phase, the app will be unblocked. During the B1 and B2 intervention phase, participants use the 'Move My it, Move ID' intervention only consisting of the buddycomponent. During the intervention period, adolescents and buddies are asked to wear an accelerometer. During the first AB pair we examine whether the buddy component has an effect on PA compared to no intervention. In the A2 reversal phase possible carryover effects can be measured. It will be informative to investigate whether some parts of the intervention are automatized or internalized and will still have some effect even when participants have no access to the intervention anymore (i.e. A2 phase). The study duration is 32 days; each phase will have a duration of minimum 5 days.
Study NCT05149443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: theory-based mHealth-intervention (app)
Description: After the first study, other participants will be recruited. In a second study, the set-up remains the same, but the A1 and A2 phase this time consist of the buddy component (i.e. control phase) and in the B1 and B2 phase the gamification component will be added. This way, we can determine whether the gamification component has an effect on PA compared to the baseline buddy component intervention.~The study duration is 32 days for all participants. The duration of the 4 different phases of the design will vary between participants, but each phase will have a duration of minimum 5 days.
Study NCT05486455 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-dose chest CT scan
Description: baseline, 1-year, 3-year and 5-year low-dose CT scan
Study NCT04516512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: For each participants to the research a peripherical blood draw will be performed
Study NCT05225974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide injection
Description: At a single dose of 0.6 mg of Liraglutide injection by subcutaneous injection
Study NCT05225974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide injection(Victoza®)
Description: At a single dose of 0.6 mg of Liraglutide injection(Victoza®) by subcutaneous injection
Study NCT05410366 — intervention group
Intervention type: OTHER
Intervention: Safe harbor clinical practice guideline
Description: A safe harbor is a special type of clinical practice guideline which, under existing federal law, may serve as the legal standard of care, not just evidence of the standard of care. If a patient with a safe harbor condition satisfies all safe harbor inclusion criteria and does not meet any exclusion criteria, no imaging is required, and the patient may be discharged with specific instructions. If a patient is excluded from the safe harbor, then imaging decisions are per customary practice. The safe harbor clinical practice guidelines are provided to treating ED physicians, but they are not obligated to use them. The safe harbor pathways do not limit the diagnostic and therapeutic approach patients and physicians undertake during a clinical encounter. They have the liberty in this decision to proceed jointly down a clinical pathway most appropriate to the individual clinical circumstance.
Study NCT05304611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection
Description: Administered one time via subcutaneous route.
Study NCT00893854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Study NCT05582681 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cepheid POC HCV Viremia (RNA) test
Description: The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is a test designed for the quantitation (amount) of Hepatitis C Virus (HCV) DNA in human whole blood. The HCV RNA result will be compared to standardized laboratory assessment for HCV Viremia. The Cepheid test is for being conducted for research use only and will not be used for HCV diagnosis or treatment decisions.
Study NCT05582681 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HCV education from a health care provider
Description: HCV education provided by health care provider. HCV Education will include HCV disease overview, HCV screening, treatment with G/P, and post treatment assessment and management
Study NCT05582681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCV education from a health care provider
Description: HCV education provided by health care provider. HCV Education will include HCV disease overview, HCV screening, treatment with G/P, and post treatment assessment and management
Study NCT05582681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glecaprevir and Pibrentasvir
Description: G/P will be provided for 8 weeks.
Study NCT05582681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir and Pibrentasvir
Description: G/P will be provided for 8 weeks.
Study NCT05812352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio kit
Description: MP3 audio files for each of 6 steps and instructional flashcard with pictures corresponding to each of the 6 steps of tourniquet application
Study NCT05812352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructional flashcard
Description: Single page (instructional flashcard) with pictures corresponding to each of the 6 steps of tourniquet application
Study NCT05304611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L9LS (VRC-MALMAB0114-00-AB) intravenous injection
Description: Administered one time via intravenous route.
Study NCT05304611 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline administered one time via subcutaneous route.
Study NCT05812352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person training
Description: Stop the Bleed bleeding control (B-Con) course is used for instruction for tourniquet application attempt
Study NCT05379894 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous nephrolithotripsy
Description: Extraction of kidney stones through skin using nephroscope
Study NCT06563310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) with Veritable-NF
Description: Participants will complete 4 visits (some can be done virtually). The baseline visit will include a clinical interview. Eligible participants will complete a series of questionnaires and a practice session at visit 2, and may do a mock scan if the visit is in person. Visit 3 will take place within 5 days of the practice session. Participants will have an fMRI with real neurofeedback and answer a series of questions pertaining to the scan. 2 weeks after visit 3, participants will revisit the questionnaires they completed at baseline. Visit 4 will take place one month after visit 3 and will include a follow-up interview with an assessor and the final questionnaire collection.
Study NCT06563310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fMRI with Sham-NF
Description: Participants will complete 4 visits (some can be done virtually). The baseline visit will include a clinical interview. Eligible participants will complete a series of questionnaires and a practice session at visit 2, and may do a mock scan if the visit is in person. Visit 3 will take place within 5 days of the practice session. Participants will have an fMRI with neurofeedback that looks similar to real neurofeedback but does not reflect their true brain signal. Afterwards, they will answer a series of questions pertaining to the scan. 2 weeks after visit 3, participants will revisit the questionnaires they completed at baseline. Visit 4 will take place one month after visit 3 and will include a follow-up interview with an assessor and the final questionnaire collection.
Study NCT05640856 — intervention group
Intervention type: PROCEDURE
Intervention: intubation
Description: Endotracheal tube placement
Study NCT05067452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food support
Description: Diabetes-tailored food support. Project Open Hand will provide intervention participants twelve weeks of supplemental food support. Food support will consist of a mix of meals tailored for T2DM, and T2DM-healthy groceries, consistent with American Diabetes Association (ADA) guidelines for diabetes healthy diets under the responsibility of a registered dietitian. All food support will be home delivered.
Study NCT05067452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case-management
Description: Project Open Hand client services staff will conduct three case management sessions with the participant. The first session will initiate food services and ensure orientation to the intervention and set up delivery; the second session will support the participant with any issues related to the intervention (logistical or nutrition-related, with referral to the POH registered dietitian as needed); the third session will provide transition from the intervention, connect the participant with local food resources, and ensure a warm hand-off to nutrition
Study NCT05962255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide intravenous infusion
Description: At baseline, patients will receive a standardised dose of furosemide 1mg/kg (half of the dose administered as bolus and half as in 2h infusion).~At the 6th and the 12th hour of the study patients will be reassessed and the need for additional diuretics.
Study NCT05962255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide intravenous infusion
Description: At baseline, patients will receive a standardised dose of furosemide 1mg/kg (half of the dose administered as bolus and half as in 2h infusion).~At the 6th and the 12th hour of the study patients will be reassessed and the need for additional diuretics.
Study NCT05962255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continous intravenous infusion of 0.9% Sodium Chloride solution
Description: Continuous 48h infusion of 0.9% sodium chloride at a fixed rate v= 83 ml/h x 24h = 2l/24h
Study NCT05962255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continous intravenous infusion of 5% Glucose solution
Description: Continuous 48h infusion of 5% Glucose at a fixed rate v= 83 ml/h x 24h = 2l/24h
Study NCT05535114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga-resistance exercise
Description: Breathing exercise (5 minutes), flexibility (5 minutes), resistance exercise (20 minutes), relaxation \& meditation (10 minutes).
Study NCT05208723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and emotion management
Description: The handbook materials and lay helper scripts are based on principles of Acceptance and Commitment Therapy (ACT), and aims to enhance psychological flexibility. Psychological flexibility reflects how a person adapts to fluctuating situational demands, reconfigures mental resources, shifts perspective, and balances competing needs. ACT teaches alternative methods to accommodate difficult thoughts and feelings, primarily through mindfulness techniques. At the same time, ACT also focuses on guiding participants to live in ways consistent with their personal values.
Study NCT05376722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pamiparib
Description: pamiparib 40 mg orally, twice a day
Study NCT05376722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone
Description: biraterone acetate 1000 mg orally, once a day
Study NCT05376722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: prednisone acetate tablets (prednisone) 5 mg, once a day
Study NCT05572879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuCorVac-19
Description: COVID-19 vaccine
Study NCT05572879 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1 nCoV-19
Description: COVID-19 vaccine
Study NCT06371664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Tray (1 mm)
Description: General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of conventional individualized bleaching trays (trimmed 1 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours
Study NCT06371664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Tray (3 mm)
Description: General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of extended individualized bleaching trays (trimmed 3 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours
Study NCT05152277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: Administered SC once
Study NCT05152277 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered SC once
Study NCT05152277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: Administered SC for multiple dose
Study NCT05152277 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered SC for multiple dose
Study NCT04724304 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Real-Time Myocardial Echocardiography (RTMPE)
Description: Uses sound waves (ultrasound) to produce an images of the heart. During RTMPE a microbubble contrast agent is administered through an intravenous line (IV) to make the images of your heart clearer.
Study NCT04724304 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance image (MRI)
Description: Imaging that focuses on the heart or blood vessels to assess size and function of the heart's chambers, thickness and movement of the walls of the heart, and blood flow in the blood vessels.
Study NCT04348539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Description: 32 sessions will be held twice a week, with each session taking an average of 45 minutes
Study NCT05688072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: trunk oriented exercise
Description: trunk oriented exercises include: stretching exercises, stabilization exercises (active or active-assisted), arm exercises in fixed trunk position, trunk-oriented exercises (active or active-assisted), trunk mobilization (sitting and lying position), and functional reaching exercises with different ranges of motion in shoulder elevation
Study NCT05688072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole body vibration
Description: WBV application technique. The children assume a full squatting position on a vibration platform. The apparatus will set at a frequency of 30 Hz, an amplitude of 2 mm, and a duration of 5 min. The children were instructed to remain in squatting position after the vibration started and to report any discomfort that arose. At the end of 5 min, the vibration turned off automatically. Thereafter, the children rested for 1 min. They were then asked to stand on the vibration platform while supported by the therapist for 5 min, with the same parameters as those used in the squatting position. The total time of application of WBV in each session was 10 min.
Study NCT04781907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Expansion
Description: Tissue expanders are used to increase the soft tissue envelope after mastectomy to provide adequate and healthy coverage of prosthetic breast implants.
Study NCT05966493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lufepirsen
Description: Lufepirsen is an unmodified connexin43 antisense oligonucleotide.